Best Life Sciences Companies in Newton, United States
The 40 best Life Sciences companies in Newton, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Abcuro.
Our analysis of 164 Life Sciences companies
$34.7b in tracked funding; 83% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences companies in Newton
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Abcuro Developer of immune-modulatory bio-therapeutics for autoimmune diseases and cancer 42Funding top 22%Moat top 28%Growth top 35%Patents top 35% All 9 signals ▾Fundingtop 22% Moattop 28% Growthtop 35% Patentstop 35% Innovationtop 36% Globalbottom 42% Marketbottom 32% Techbottom 19% Newsbottom 17% Funding: Raised $252M across 6 rounds · 6 rounds over 10 yrs (0.6/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 48 patents rank vs industry peers · Fliar Intelligence Index 42/100 | $252M | 18 mo ago | 24 24 → 40 (+67%) | — | WordPressMySQLPHP+13 | 48 patents Therapeutic antibodies targeting KLRG1 for immune‑mediated diseases and leukemias | — |
| 2 | OmniGuide Developer of laser and robotic systems for surgical purposes | $130M | 155 mo ago | 60 | Yoel Fink Co-Founder | WordPressMySQLPHP+21 | 58 patents Surgical laser waveguide delivery and laparoscopic handpiece locking mechanisms | — |
| 3 | Stealth BioTherapeutics Developer of peptide therapy to treat rare mitochondrial diseases and its dysfunction-related disorders | $100M | 76 mo ago | 31 31 → 75 (+142%) | Reenie McCarthy CEO | WordPressApple iCloud MailMySQL+21 | 291 patents Peptide-based therapeutics for neurodegenerative, cardiac, and rare genetic disease treatment | 1 award |
| 4 | Karyopharm Biopharmaceutical company focused on developing and commercializing innovative cancer therapies 69Funding top 17%News top 26%Market top 32%Tech top 34% All 9 signals ▾Fundingtop 17% Newstop 26% Markettop 32% Techtop 34% Moattop 42% Fin. healthtop 43% Talenttop 45% Growthbottom 49% Globalbottom 49% Funding: Raised $98.4M across 12 rounds · 12 rounds over 16 yrs (0.8/yr) News: 30 BI events in 12 mo (of 119 tracked, 8 types) · +114% YoY rank vs industry peers · Fliar Intelligence Index 69/100 | $98M | 5 mo ago | 325 325 → 320 (-2%) | Michael Kauffman Cofounder | WordPressApple iCloud MailMySQL+27 | — | — |
| 5 | Allena Developer of protein therapeutics to treat nephrology and urological conditions | $96M | 71 mo ago | 21 | Lou Brenner CEO | — | 3 patents Quantitative analytical methods for measuring antibiotics and calicheamicin in bone tissue | — |
| 6 | Alcresta Developer of enzyme-based products for gastrointestinal disorders | $96M | 78 mo ago | 52 52 → 106 (+104%) | — | — | 41 patents Targeted dietary fatty acid supplementation formulations and delivery devices | — |
| 7 | Cheetah Medical Non-invasive cardiac output and hemodynamic monitoring device | $90M | 90 mo ago | 73 | — | — | — | — |
| 8 | Matritech Protein-based point-of-care diagnostic tests | $56M | 235 mo ago | — | Namal Nawana CEO | — | 13 patents Molecular diagnostics and therapeutic biomarkers for breast and cervical cancer detection. | — |
| 9 | Synchroneuron Improved formulation of acamprosate calcium for neurpschiatry disorders | $26M | 145 mo ago | 1 | William Kerns Co-Founder | — | 56 patents Acamprosate pharmaceutical formulations and combination therapies for alcohol dependence | — |
| 10 | Adaptilens Developer of intraocular lens | $19M | 28 mo ago | 5 | Liane Clamen Founder & CEO | — | 14 patents Biostable polymer brush materials and delivery mechanisms for advanced intraocular lenses | — |
| 11 | Jana Care Provider of mobile-based healthcare diagnostics for diabetes prevention 53Innovation top 27%Funding top 30%Product top 32%Moat top 39% All 8 signals ▾Innovationtop 27% Fundingtop 30% Producttop 32% Moattop 39% Markettop 45% Talentbottom 49% Globalbottom 39% Techbottom 22% Innovation: 3 product lines · Deep-tech classification: Tech Hardware Funding: Raised $17.7M across 8 rounds · 8 rounds over 14 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 53/100 | $18M | 5 mo ago | 60 | Anh Hoang Chief Executive Officer | — | — | — |
| 12 | Diceros Therapeutics Developer of therapeutics for the treatment of chronic rhino sinusitis | $13M | 47 mo ago | — | Stephen R Seiler CEO | — | — | — |
| 13 | Siamab Monoclonal antibodies for cancer | $10M | 94 mo ago | 4 | — | — | — | — |
| 14 | Atreaon Developing treatment for the arthritis | $8M | 178 mo ago | — | David Y. Sun Co-Founder | — | — | — |
| 15 | GelMEDIX Developer of a hydrogel drug delivery technology for ophthalmic treatment | $6M | 6 mo ago | 9 | Nasim Annabi Co-Founder | — | 26 patents Hydrogel-based biomaterials for cell encapsulation and tissue engineering | — |
| 16 | Biosensics Wearable medical devices and digital health technologies for clinical trials | $3M | 15 mo ago | 14 14 → 19 (+36%) | Ashkan Vaziri CEO | — | 9 patents Wearable medical monitoring and fall detection/rehabilitation systems for limb function. | 1 partnership |
| 17 | NeuroFieldz AI-powered mobile eye and brain diagnostics for neuro-visual disorders | $3M | 12 mo ago | 3 | Srinivas Sridhar founder | — | — | — |
| 18 | Anew Optics Developer of intraocular lens ophthalmic disorders | $3M | 164 mo ago | — | — | — | 39 patents Intraocular lens haptic structures and capsular opacification‑blocking designs | — |
| 19 | BioXyTran Developing platform technologies in Glycovirology, Hypoxia, and Degenerative Diseases | $2M | 5 mo ago | 3 | — | Webflowcore-jsjQuery+10 | 2 patents Patents concentrated in health & consumer products | — |
| 20 | Newton Photonics Develops non-invasive glucometer | $2M | 158 mo ago | — | Paul Melman Co-Founder & CTO | — | — | — |
| 21 | MHB Labs A pharmaceutical product addressing unmet needs within men's health | $1M | 137 mo ago | — | Ravi Kacker Founder & CEO | — | 8 patents Patents concentrated in health & consumer products | — |
| 22 | Precision Healing Provider of diagnostics solutions for wound care & precision healing | $920K | 69 mo ago | 7 | W Lee CEO | — | — | — |
| 23 | NeuroHealing Pharmaceuticals Developer of re-purpose molecules for the treatment of coma recovery, sialorrhea and premature ejaculation | $691K | 166 mo ago | 4 | — | — | — | — |
| 24 | Ovatemp Online platform offering thermometer and app for fertility tracking | $120K | 137 mo ago | 2 | Ana Mayer Co-Founder & Chief Fertility Officer | — | 2 patents Portable electronic fertility monitoring devices and related data analysis systems | — |
Top 12 Life Sciences companies in Newton
#1
Public · Newton, Massachusetts · founded 2008 · 325 employees$98.4Mraised▾
Biopharmaceutical company focused on developing and commercializing innovative cancer therapies. It leverage proprietary scientific platforms to target key mechanisms of disease and address unmet needs in oncology through clinical research and drug development programs. It focuses on addressing complex cancers by investigating innovative mechanisms of action designed to disrupt disease progression at the cellular level. Its scientific approach is built around proprietary technology platforms aimed at modulating key biological processes involved in cancer development and survival.
- Mar 2026Post IPO$30M
- Oct 2025Post IPO$8.8M
- Dec 2022Post IPO$165M
- Oct 2018Post IPO$22.5M
#2
Series C · Newton, New Jersey · founded 2011 · 60 employees$17.7Mraised▾
JanaCare is a healthcare technology startup providing a diagnostic device and a mobile-based platform for diabetes management. The device can measure blood glucose, lipids, creatinine, and hemoglobin. Its Habits program available both on the web and through a mobile application is based on the diabetes prevention program curriculum. The mobile app "food: habits" tracks user's calories and fat intake provides suggestions for meals, aids to set calorie burning and weight loss goals.
- Mar 2026Series C$1.4M
- Mar 2025Series C$2.9M
- Oct 2023Series C$13.1M
- Nov 2022Series B$575.3K
#3
Series C · Newton, Massachusetts · founded 2015 · 24 employees$251.8Mraised▾
Developer of immune-modulatory bio-therapeutics for autoimmune diseases and cancer. It offers ABC008 an anti-KLRG1 antibody for autoimmune muscle disease inclusion body myositis, T cell large granular lymphocytic leukemia, and mature T cell malignancies, ABC015 is a monoclonal antibody for cancer treatment.
- Feb 2025Series C$200M
- Aug 2023Series B$199.5M
- Jan 2021Series A$42M
- Aug 2019Grant (prize money)$164.1K
#4
Seed · Newton, Massachusetts · founded 2019 · 9 employees$6.4Mraised▾
Developer of a hydrogel drug delivery technology for ophthalmic treatment. It offers a lead product GMX-101 a retinal pigment epithelial (RPE) cell therapy that targets Geographic Atrophy.
- Feb 2026Seed$13M
- Oct 2025Seed$542K
- Jan 2025Seed$1M
- Mar 2024Conventional Debt$1.9M
#5
Acquired · Newton, Massachusetts · founded 2008 · 3 employees$2.2Mraised▾
Developing platform technologies in Glycovirology, Hypoxia, and Degenerative Diseases. It is focused on carbohydrate drug design to combat viruses and extend lifespan. It pioneers glycan-based technology, creating entry inhibitors that target viruses directly, potentially modulating the immune system. It is also developing oxygen therapeutic treatments for hypoxic conditions and necrosis prevention, targeting medical conditions like brain stroke, wound healing, and trauma.
- Mar 2026Post IPO$873.9K
- Mar 2023Post IPO$130K
- Aug 2022Post IPO$600K
- Nov 2019Post IPO$332.3K
#6
Funding Raised · Newton, Massachusetts · founded 2012 · 3 employees$2.7Mraised▾
AI-powered mobile eye and brain diagnostics for neuro-visual disorders. This innovative company is developing a medical device, currently in the development phase, that utilizes Visual Evoked Potentials (VEP) to diagnose ophthalmic and neurological conditions. Their technology offers objective neuro-optical testing with integrated visual stimulus and neuromonitoring. The portable device aims to provide new revenue streams by reducing setup and testing times, potentially enabling new diagnostic tests and expanding current clinic-based practice. The AI powered software analyzes brain signals, offering potential diagnostic tools for conditions like glaucoma, multiple sclerosis, traumatic brain injury, and macular degeneration. The system uses dry nanostructured bioelectrodes for reduced setup time and high-quality data streaming.
- Sep 2025Grant (prize money)$375.9K
- Sep 2018Grant (prize money)$225K
- Sep 2017Grant (prize money)$2M
- Jul 2015Grant (prize money)$150K
#7
Seed · Newton, Massachusetts · founded 2007 · 14 employees$3Mraised▾
Wearable medical devices and digital health technologies for clinical trials, patient monitoring, and health assessment. The company develops advanced technologies for robust collection of digital health data and precise measurement of disease symptoms. They offer comprehensive operational and technical services for clinical trials and research. The company pioneers the use of wearable sensors and digital health technologies in healthcare and clinical research, creating solutions for collection of digital biomarkers and outcome assessment. They develop wearable sensors and digital platforms for clinical trials, patient monitoring and health assessment. The company's solutions empower novel healthcare initiatives and important clinical trials in a variety of therapeutic areas. The company focuses on developing novel digital health technologies and validated biomarkers for neurological and rare disorders.
- Jun 2025Grant (prize money)$2M
- May 2025Grant (prize money)$275K
- Mar 2025Grant (prize money)$4.6M
- Mar 2025Grant (prize money)$400K
#8
Series A · Newton, Massachusetts · founded 2018 · 5 employees$19.1Mraised▾
Adaptilens has developed intraocular lens that is injected into the eyes. The company has developed Adaptilens that's designed to be injected into the eye to retain its elliptical shape by allowing the ciliary muscles of the eyes to modify the lens shape and focus on the objects to view them clearly.
- Apr 2024Series A$17.5M
- Jun 2021Grant (prize money)$87.5K
- Nov 2020Seed$1.6M
#9
Seed · Newton, Massachusetts · founded 2019 · 11 employees$75Kraised▾
Xheme developed a technology platform by making blood bags that are capable of increasing the shelf life of whole blood and platelets. The company's patented technology, the nanocomposite blood bag is designed in such a way so that no additives leach into the blood to alter the blood composition. It increases the shelf life of blood with the help of the antioxidant activity of nanoparticles.
- Sep 2025Seed$40K
- Oct 2023Seed$50K
- Jul 2021Grant (prize money)$255.9K
- Oct 2020Seed$25K
#10
Acquired · Newton, Massachusetts · founded 2011 · 52 employees$95.9Mraised▾
Developer of enzyme-based products for gastrointestinal disorders. Its platform technology immobilizes enzymes and attaches them to an insoluble carrier, that can be used to support the digestion and absorption of essential nutrients. Its flagship product Relizorb is a digestive enzyme cartridge that has been designed to mimic the function of pancreatic lipase.
- Feb 2020Series D$10M
- Jan 2019Series D$5M
- Sep 2017Series D$10M
- Mar 2016Series C$50.9M
#11
Public · Newton, New Jersey · founded 2011 · 21 employees$96Mraised▾
Allena is developing and commercializing non-systemic protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrology and urologic conditions. The company’s approach enables the design and development of oral protein therapies that remain in the gastrointestinal (GI) tract, where the protein exerts its therapeutic effect by reducing toxic metabolites without being absorbed into the bloodstream. Allena’s lead program, ALLN-177, is in an ongoing Phase 2 clinical trial and is being developed for the chronic management of hyperoxaluria and kidney stones.
- Sep 2020Post IPO—
- Jul 2020Post IPO$5M
- Dec 2015Series C$53M
- Dec 2014Series B$25M
#12
Series F · Newton, New Jersey · founded 2000 · 60 employees$130.1Mraised▾
Developer of laser and robotic systems for surgical purposes. The company's products include CO2 laser systems, instrumentation robotics, FMX Ferromagnetic, Holmium laser system, and more.
- Sep 2013Series F$15M
- Aug 2012Series F$35M
- Mar 2011Series E$3.5M
- Sep 2009Series E$250K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in the United States
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 6,260 United States-affiliated papers.
- Harvard University209
- Cornell University177
- University of Tennessee at Chattanooga140
- Howard Hughes Medical Institute126
- Johns Hopkins University121
- Gene33→164
- Transcription (linguistics)11→79
- Antibody11→62
- Genome6→56
- Mutation7→56
- Gene8→110
- Cell culture3→62
- Gene expression3→62
- Fermentation2→54
- Downregulation and upregulation1→50
- Agriculture19→58
- Antibiotic resistance15→45
- Public health4→31
- Gene6→30
- Production (economics)5→29
Where biotechnology is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing biotechnology patents in the United States
United States biotechnology patent filing is accelerating — 457,918 filings from 8,000 assignees (2016–2025), led by Genentech, UNIV California, Regeneron Pharma; annual filings 36884→44446.
- Genentech18078
- UNIV California17948
- Regeneron Pharma16082
- Amgen10495
- Monsanto Technology9742
- UNIV Pennsylvania8521
- Harvard College7460
- UNIV Texas7378
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.